Vaxcyte, Inc.
PCVX
Classement en actions
#2112
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Prix de l'action
$63.40
Dernière synchronisation: 2026-10-16
Capitalisation boursière
$9.72B
Changement (1 jour)
-2.87%
Changement (1 an)
49.56%
Pays
US
Échange Vaxcyte, Inc. (PCVX)
Catégorie
Healthcare
EPS pour Vaxcyte, Inc. (PCVX)
EPS au June 2026 TTM : $-7.64
Selon les derniers rapports financiers et le cours de l'action de Vaxcyte, Inc., l’EPS actuel de la société (TTM) est de $-7.64. À la fin de 2023, la société avait un EPS de $-4.14 une augmentation par rapport à celui de 2022, qui était de $-3.44.
Historique de l'EPS de Vaxcyte, Inc. de 2017 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $-7.64 | 101.05% |
| 2024 | $-3.80 | -8.21% |
| 2023 | $-4.14 | 20.35% |
| 2022 | $-3.44 | 78.24% |
| 2021 | $-1.93 | -35.02% |
| 2020 | $-2.97 | -78.94% |
| 2019 | $-14.10 | 73.65% |
| 2018 | $-8.12 | 67.77% |
| 2017 | $-4.84 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $17.32 | -326.70% |
US
|
|
| $-7.98 | 4.45% |
US
|
|
| $-5.29 | -30.76% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -463.09% |
NL
|
